Erratum: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy (SLEEP DOI: 10.1093/sleep/zsaa206)

Richard K. Bogan, Michael J. Thorpy, Yves Dauvilliers, Markku Partinen, Rafael Del Rio Villegas, Nancy Foldvary-Schaefer, Roman Skowronski, Lihua Tang, Franck Skobieranda, Karel Šonka

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the originally published version of this manuscript, there was an error under the Efficacy heading. The following text should read: “randomized to placebo (1.00 [0.00, 4.45]) or to continue LXB treatment (1.08 [0.00, 7.88])” instead of “randomized to placebo (1.08 [0.00, 7.88]) or to continue LXB treatment (1.00 [0.00, 4.45]).” This has now been corrected online.

Original languageEnglish (US)
Article numberzsab033
JournalSleep
Volume44
Issue number7
DOIs
StatePublished - Jul 1 2021

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Erratum: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy (SLEEP DOI: 10.1093/sleep/zsaa206)'. Together they form a unique fingerprint.

Cite this